Boston Scientific locks media out of shareholder meeting

Media aren't welcome at Boston Scientific's annual shareholder meeting today, the first since J. Raymond Elliott became CEO of the device maker. Boston Scientific has also been wrestling with a number of other problems. Last month the Department of Justice rejected the company's plea deal related to Guidant's concealment of safety issues with its heart device. Earlier this year BS reached a $1.7 billion patent dispute settlement with rival Johnson & Johnson, and also announced that it would cut 1,300 jobs as part of a worldwide restructuring effort. Last quarter the company reported a loss of $1.6 billion. Report

Suggested Articles

Takeda tapped Roche’s Foundation Medicine to develop tissue- and blood-based companion diagnostic tests for its portfolio of lung cancer therapies.

Cellex has announced plans to develop a rapid coronavirus test that people can fully perform at home, from sample collection to result, using an app.

More than 20 states either don’t release or have incomplete data on the rapid antigen tests now considered key to containing the coronavirus.